Fuchs, E. and Wolf, S. and Scrozynski, G. (2019): Cervical Carcinoma Prevention - Implementation of an HPV screening test for early detection of cervical cancer in Austria . HTA-Projektbericht 121.

Gartlehner, G. (2007): [New vaccines: Horizon scanning]. HTA-Newsletter 59: p. 4.

Harrington, P. and Lucey, D. and O’Brien, K. and Jordan, K. and Moran, P. and Marshall, L. and Wilbacher, I. and Gloeckner, L. (2019): C-reactive protein point-of-care testing (CRP POCT) to guide antibiotic prescribing in primary care settings for acute respiratory tract infections. EUnetHTA-Report . HTA-Projektbericht 116.

Huic, M. and Reinsperger, I. (2023): Oral and parenteral preexposure prophylaxis (PrEP) to prevent HIV in people at risk: a systematic review of clinical effectiveness and safety with assessment of organisational, economic, patients/social, ethical and legal elements. HTA-Projektbericht 152.

Huić, M. (2021): Bamlanivimab monotherapy and as combination therapy (with Etesevimab) for Covid-19. AIHTA Policy Brief 009.

Huić, M. and Swiss Network for HTA, (SNHTA) (2021): Combination therapy Casirivimab plus Imdevimab (REGN-COV2) for the treatment of Covid-19. AIHTA Policy Brief 008.

Jonas, S. and Jessner, W. and Rafetseder, O. and Wild, C. (2004): [Chronic hepatitis C: Implications for therapy and economic resources in Austria]. ITA-Projektbericht 26.

Jonas, S. and Wild, C. and Schmetterer, L. and Sycha, T. and Frank, W. (2001): [Immunoglobulins in transplant medicine: Prevention and therapy of cytomegalovirus infections. Systematic review and meta-analysis]. ITA-Projektbericht 19.

Jonas, S. and Jessner, W. and Rafetseder, O. and Wild, C. (2005): [Chronic hepatitis C in Austria]. Mitteilungen der Sanitätsverwaltung 01: pp. 5-7.

Kisser, A. (2016): Hepatitis C virus screening in hospitals. Decision Support Document 102.

Kisser, A. and Zechmeister-Koss, I. (2013): P16/Ki-67 Dual Stain in the triage of PAPIII/IIID cytology in cervical cancer screening . HTA-Projektbericht 72.

Piso, B. and Reinsperger, I. (2015): Vaccination against human papillomavirus (HPV). Decision-aid for young women and girls. Decision Support Document 79.

Sprenger, M. (2005): [Oseltamivir (Tamiflu)]. HTA-Newsletter 43: pp. 1-2.

Wild, C and Wolf, S and Goetz, G and Walter, M and McEntee, J and Stanak, M and Ettinger, S and Strohmaier, C and Erdos, J and Huić, M (2020): Covid-19: HSS/ Horizon Scanning Living Document. AIHTA Policy Brief 002.

Wild, C. (2006): [Antiviral treatment for chronic hepatitis C]. HTA-Newsletter 45: p. 4.

Wild, C. (2005): [Immunoglobulin in neonates and preterm infants]. HTA-Newsletter 41: pp. 2-3.

Wild, C. (2005): [Recombinant activated C protein for severe sepsis]. HTA-Newsletter 38: p. 4.

Wild, C. (2004): [Prevention and therapy of Hepatitis C]. HTA-Newsletter 29: pp. 3-4.

Wild, C. (2003): [Activated protein C for severe sepsis]. HTA-Newsletter 18: p. 2.

Wild, C. (2003): [Use of genotypic resistance testing to optimise HIV-therapy]. HTA-Newsletter 14: p. 3.

Wild, C. (2002): [Vaccines for preventing influenza]. HTA-Newsletter 07: pp. 3-4.

Wild, C. (2002): [Antifungal agents in the treatment of invasive aspergillosis]. HTA-Newsletter 04: p. 4.

Wild, C. (2001): [Cytomegalovirus prophylaxis and therapy]. HTA-Newsletter 02: pp. 3-4.

Wild, C. (2000): [The C-reactive protein test in the diagnosis of infections]. ITA-Newsletter September 2000: p. 3.

Wild, C. and Jonas, S. (2001): [Immunoglobulins in transplant medicine: Prevention and therapy of cytomegalovirus infections]. ITA-Newsletter September 2001: pp. 9-10.

Wild, C. and Jonas, S. and Frank, W. and Traunmüller, F. (2001): [Invasive aspergillosis: State of the art in diagnosis, treatment and conditions. An assessment]. ITA-Projektbericht 18.

Wild, C. (2001): [Immunoglobulins: Effectiveness and costs]. ORF ON Science.

Wild, C. and Jonas, S. and Frank, W. and Schmetterer, L. and Sycha, T. (2002): [Immunoglobulins in transplant medicine. Prevention and therapy of cytomegalovirus infections: An Assessment]. Transplantationsmedizin (02): pp. 65-73.

Wild, C. and Jonas, S. and Frank, W. and Schmetterer, L. and Sycha, T. (2001): [Immunoglobulins in transplant medicine. Prevention and therapy of cytomegalovirus infections: An Assessment]. European Surgery: Acta Chirurgica Austriaca 33 (Supplement 178).

Wild, C. and Piribauer, F. and Stergner, A. (2009): New influenza (swine flu) – data & facts for decision support. Decision Support Document 35.

Wolf, S. (2022): Long COVID care pathways and structures: an updated scoping review. HTA-Projektbericht 135b/ Update.

Wolf, S. and Erdos, J (2021): Epidemiology of long COVID: a preliminary report. German short version of the original KCE report. HTA-Projektbericht 135a.

Wolf, S. and Erdos, J. (2021): Long COVID care pathways: a systematic review. HTA-Projektbericht 135b.

Zechmeister, I. (2007): [Hepatitis C therapy]. HTA-Newsletter 59: p. 2.

Zechmeister, I. and Sroczynski, G. and Rafetseder, O. and Jonas, S. (2006): [Chronic hepatitis C: Decision analytic modeling]. ITA-Projektbericht 29.

Zechmeister-Koss, I. (2013): Zostavax® for the prevention of herpes zoster and postherpetic neuralagia. Pilot assessment using the draft HTA Core Model for Rapid Relative Effectiveness Assessment. Pilot-ID: WP-SA-1. Decision Support Document 73.

Zechmeister-Koss, I. and Reichel, M. (2012): Health status and access to health care of homeless people: A literature review. HTA-Projektbericht 63.